## Contents

**Highlights of This Issue** 1839

### THERAPEUTIC DISCOVERY

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1841</td>
<td>First Evidence of Sphingosine 1-Phosphate Lyase Protein Expression and Activity Downregulation in Human Neoplasm: Implication for Resistance to Therapeutics in Prostate Cancer</td>
<td>Leyre Brizuela, Isabelle Ader, Catherine Mazeronnes, Magalie Bocquet, Bernard Malavaud, and Olivier Cuvillier</td>
</tr>
<tr>
<td>1852</td>
<td>Induction of the Transcriptional Repressor ZBTB4 in Prostate Cancer Cells by Drug-Induced Targeting of MicroRNA-17-92/106b-25 Clusters</td>
<td>KyoungHyun Kim, Gayathri Chadalapaka, Satya S. Pathi, Un-Ho Jin, Ju-Seog Lee, Yun-Yong Park, Sung-Gook Cho, Sudhakar Chintharlapalli, and Stephen Safe</td>
</tr>
<tr>
<td>1873</td>
<td>Oxidative Stress Induced by Curcumin Promotes the Death of Cutaneous T-cell Lymphoma (HuT-78) by Disrupting the Function of Several Molecular Targets</td>
<td>Mohammad Aslam Khan, Satindra Gahlot, and Sekhar Majumdar</td>
</tr>
<tr>
<td>1884</td>
<td>Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the βGBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo</td>
<td>Livio Mallucci, Dong-yun Shi, Derek Davies, Peter Jordan, Alastair Nicol, Lavinia Lotti, Renato Mariani-Costantini, Fabio Verginelli, Valerie Wells, and Daniel Zicha</td>
</tr>
</tbody>
</table>

### PRECLINICAL DEVELOPMENT

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1905</td>
<td>Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-κB Pathways</td>
<td>Xinqi Wu, Jingjing Li, Meijun Zhu, Jonathan A. Fletcher, and F. Stephen Hodi</td>
</tr>
<tr>
<td>1915</td>
<td>Targeted Expression of BikDD Eliminates Breast Cancer with Virtually No Toxicity in Noninvasive Imaging Models</td>
<td>Xinhua Xie, Laisheng Li, Xiangsheng Xiao, Jiaoli Guo, Yanan Kong, Mingjing Wu, Wanli Liu, Guoquan Gao, Jennifer L. Hsu, Weidong Wei, Mien-Chie Hung, and Xiaoming Xie</td>
</tr>
<tr>
<td>1925</td>
<td>ATP Citrate Lyase Knockdown Induces Growth Arrest and Apoptosis through Different Cell- and Environment-Dependent Mechanisms</td>
<td>Nousheen Zaidi, Ines Royaux, Johannes V. Swinnen, and Karine Smans</td>
</tr>
</tbody>
</table>

The Journal of Cancer Drug Discovery & Preclinical Development iii www.aacrjournals.org

Downloaded from mct.aacrjournals.org on July 6, 2017. © 2012 American Association for Cancer Research.
Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models

Caroline C. Clark, Jeffrey N. Weitzel, and Timothy R. O’Connor

TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells

Daniel P. Fitzgerald, David L. Emerson, Yongzhen Qian, Talha Anwar, Hong-Bin Fang, Ling Cai, Zhe-Sheng Chen, Suresh V. Ambudkar, and Maria R. Baer

Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target

Yongli Guo, Fadzai Chinyengetere, Andrey V. Dolinko, Alexandra Lopez-Aguiru, Yun Lu, Fabrizio Galimberti, Tian Ma, Qingsheng Cheng, David Sekula, Sarah J. Freemantle, Ethan Dmitrovsky

Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib


YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels

Bhavna Kumar, Arti Yadav, James C. Lang, Michael J. Cipolla, Alessandra C. Schmitt, Nicole Arradaza, Theodoros N. Teknos, and Pawan Kumar

The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models

Masamichi Mizuma, Zeshaan A. Rasheed, Shinichi Yabuuchi, Noriyuki Omura, Nathaniel R. Campbell, Roeland F. de Wilde, Elizabeth De Oliveira, Qing Zhang, Oscar Puig, William Matsui, Manuel Hidalgo, Anirban Maitra, and N.V. Rajeshkumar

Fibroblast Growth Factor Receptor 2 IIIC as a Therapeutic Target for Colorectal Cancer Cells

Yoko Matsuda, Masahito Hagio, Tomoko Seya, and Toshiyuki Ishiwata

Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion


The Novel BCR-ABL andFLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2

Rupashree Sen, Karthika Natarajan, Jasjeet Bhullar, Suneet Shukla, Hong-Bin Fang, Ling Cai, Zhe-Sheng Chen, Suresh V. Ambudkar, and Maria R. Baer

MLN0905, a Small-Molecule PLK1 Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma

Judith Quijia Shi, Kerri Lasky, Vanhali Shinde, Bradley Stringer, Mark G. Qian, Debra Liao, Ray Liu, Denise Driscoll, Michelle Tighe Nestor, Benjamin S. Amidon, Youlan Rao, Matt O. Duffey, Mark G. Manfredi, Tricia J. Vos, Natalie D’ Amore, and Marc L. Hyer

Genetic Variation That Predicts Platinum Sensitivity Reveals the Role of miR-193b-5p in Chemotherapeutic Susceptibility

Dana Ziliak, Eric R. Gamazon, Bonnie LaCroix, Hae Kyung Im, Yujia Wen, and Rong Stephanie Huang

Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials

Rodrigo Dienstmann, Danila Serpico, Jordi Rodon, Cristina Saura, Teresa Macarulla, Elena Elez, Maria Alsina, Jaime Capdevila, Jose Perez-Garcia, Gessami Sanchez-Ollé, Claudia Aura, Ludmila Prudkin, Stefania Landolfi, Javier Hernandez-Losa, Ana Vivancos, and Josep Tabernero

Correction: Proanthocyanidins Inhibit In Vitro and In Vivo Growth of Human Non–Small Cell Lung Cancer Cells by Inhibiting the Prostaglandin E2 and Prostaglandin E2 Receptors

American Association for Cancer Research

Downloaded from mct.aacrjournals.org on July 6, 2017. © 2012 American Association for Cancer Research.
Immunohistochemical staining of colorectal cancer tissues using anti-FGFR2IIIC antibody. The tumor cell cytoplasm and cell membrane of adenocarcinoma showed strong immunoreactivity for FGFR2IIIC, which is a splicing isoform of FGFR2. FGFR2IIIC immunoreactivity was expressed in 27% of colorectal cancer cases, and this expression correlated with distant metastasis and poor prognosis. FGFR2IIIC-transfected colorectal cancer cells formed larger tumors in subcutaneous tissues and the cecum of immunodeficient mice. Fully human anti-FGFR2IIIC monoclonal antibody inhibited the growth and migration of colorectal cancer cells. For details, see the article by Matsuda and colleagues on page 2010.